Investor Expectations for the Life Sciences Sector
A panel of healthcare and finance experts will discuss the results from FTI Consulting's Fourth Annual Life Sciences Survey and explore the market dynamics currently driving investment decisions and transactions in the industry.
Thursday, March 13, 2014
10 a.m. EDT
60 mins

Reserve Your Spot


Judy BrownExecutive Vice President and Chief Financial Officer, Perrigo Company Judy Brown is an executive vice president and chief financial officer at Perrigo Company, a leading global manufacturer and distributor of over-the-counter (OTC) pharmaceuticals. At Perrigo, she has overseen the acquisition of Dublin-based biotechnology company, Elan. She currently is on the board of directors at Belden Corporation (NYSE: BDC), a connectivity and networking products manufacturer.
  • Learn About

    • Investors’ outlook for healthcare and life sciences stock performance
    • Key drivers of investment decisions, and valuations for public and private companies
    • Expectations for industry IPOs and M&A activity in 2014
    • Regulations impacting the sector and transaction environment
    • Key trends in shareholder engagement and communication strategies for enhancing enterprise value

Alan HartmanPartner, Centerview Partners Alan Hartman is a partner at New York-based investment-banking and private-equity firm, Centerview Partners. With more than 20 years of experience in mergers and acquisitions, he has established himself as a leading expert in healthcare-industry transactions -- having recently advised Pfizer in its $68 billion acquisition of Wyeth, and $12 billion sale of its nutrition business to Nestle; and Onyx in its $10.4 billion sale to Amgen.

  • Who Should Attend?

    • Buy-Side Investors
    • Business Development Professionals
    • Chief Communications Officers (CCOs)
    • C-Suite Executives
    • Investment Bankers
    • Investor Relations Officers (IROs)
    • Lawyers
    • Sell-Side Analysts
    • Venture Capitalists

Healthcare & Life Sciences

  • About the Research

    FTI Consulting’s Fourth Annual Life Sciences Investor Survey assesses European and U.S. investors’ insights and expectations around a number of key industry-related topics. The study’s findings underscore investors’ overall optimism toward the outlook for healthcare stock performance and the anticipated continued strength of the transaction environment in the sector. The research also reveals a number of key trends in shareholder engagement for healthcare and life sciences companies to consider.

Tom CrawfordSenior Managing Director, Government Affairs, FTI Consulting Tom Crawford is a senior managing director in the Strategic Communications segment at FTI Consulting and serves as head of its Government Affairs specialty practice (formerly C2 Group) in the Americas. He has worked on every budget reconciliation and tax-measure package considered by the U.S. Congress in the past two decades, and has represented some the largest and most eminent financial-services and life-insurance companies.
Barbara RyanManaging Director, Financial Communications, FTI Consulting Barbara Ryan is a managing director in the Strategic Communications segment at FTI Consulting, and is based in New York. Ms. Ryan has more than 30 years of Wall Street experience as a sell-side analyst and is an expert on the biopharmaceutical and healthcare industry. She has been widely published as an authority on the trends and outlook for the global pharmaceutical industry; and is a regular, guest contributor to CNBC. Prior to FTI Consulting, Ms. Ryan was a managing director at Deutsche Bank, and head of its pharmaceutical-research teams.